JAGUAR HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2585 USD | -9.84% |
|
-11.50% | +70.74% |
| May. 17 | Jaguar Health Plans 1-for-60 Reverse Split Next Week | MT |
| May. 14 | Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 15.11M | Sales 2025 * | 22.66M | Capitalization | 71.4M |
|---|---|---|---|---|---|
| Net income 2024 * | -26M | Net income 2025 * | -21M | EV / Sales 2024 * | 4.73 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.15 x |
| P/E ratio 2024 * |
-2.87
x | P/E ratio 2025 * |
-3.69
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Jaguar Health, Inc.
More press releases
| 1 day | -9.84% | ||
| 1 week | -11.50% | ||
| Current month | +20.40% | ||
| 1 month | +56.76% | ||
| 3 months | +230.99% | ||
| 6 months | -36.41% | ||
| Current year | +70.74% |
1 week
0.25
0.33
1 month
0.150.36
Current year
0.050.36
1 year
0.050.75
3 years
0.05513.00
5 years
0.053 825.01
10 years
0.05148 365.15
| Managers | Title | Age | Since |
|---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 13-06-05 |
Carol Lizak
DFI | Director of Finance/CFO | 60 | 19-04-30 |
| Chief Tech/Sci/R&D Officer | 60 | 17-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 13-06-05 |
James Bochnowski
CHM | Chairman | 80 | 14-01-31 |
John Micek
BRD | Director/Board Member | 71 | 16-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.2585 | -9.84% | 58,064,970 |
| 24-05-16 | 0.2867 | +12.39% | 31,266,489 |
| 24-05-15 | 0.2551 | -7.20% | 25,164,148 |
| 24-05-14 | 0.2749 | -5.30% | 63,969,137 |
| 24-05-13 | 0.2903 | -0.62% | 24,976,434 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
Calendar
2024-06-21
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2585
USD
Average target price
0.6
USD
Spread / Average Target
+132.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +70.74% | 71.4M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- JAGX Stock
